Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Retatrutide for Sale > Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg
Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg buy - large image1
Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg buy - image1
Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg buy - image2

Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg

TDS 7467 Inquiries

Unit Price:

$5/UNIT FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Shanghai

Brand:

JPH

Packaging:

5mg/vial 10vials/box

Price valid (until):

2027-06-21

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
5 days
Qualification:
Main Products:

Tirzepatide,Polypeptide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Tirzepatide  is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide. Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 1

    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 2 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 3 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 4 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 5 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 6 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 7 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 8 Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 9

    Items Specifications
    Product Name Tirzepatide
    CAS number 2381089-83-2
    Purity 99%


     shipping 


    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 10
    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 11


      Company 


    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 12
    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 13
    Shop Factory high-quality weight loss peptide Tirzepatide 2023788-19-2 20 mg 30 mg-Detailed Image 14
    Why choose  us?

    1. Powerful R & D team
    2. The ability of quantized production from grams to tons;
    3. Various kinds of advanced equipment in the laboratory and plant;
    4 .Strict QC standard to meet the demand of customers, advanced equipment for analysis and assay;
    5. Efficient and safe logistic plans for chemical products transportation;
    6 .Excellent after-sale service.
    7. Highest quality and good package
    8 .ISO certificate


      FAQ  


    Is tirzepatide available for weight loss?

    It's also FDA approved for chronic weight management in adults with or without diabetes. Along with diet and exercise, tirzepatide can lead to significant weight loss — an average of 15% to 20% (34 lbs to 48 lbs). But tirzepatide for weight loss is only recommended for people who meet certain BMI criteria.

    How fast do you lose weight on tirzepatide?

    How quickly you lose weight depends on factors like lifestyle habits, diet, activity level, age, and other medications you may be taking. However, most people who follow a healthy diet and exercise routine begin reporting some weight loss within a month to two months of starting the medication.

    Which payment is available for your company?

    Bank Transfer,Paypal or Bitcoins usdt trc usdt erc and so on.  You can choose the way which is convenient for you.

    May I get one sample before placing order?

    Yes, Sample are available. For normal products, samples are for free and you just need to bear the freight; For those high value products, you just need to freight and certain product cost. When we both cooperate for some times or when you are our VIP customer, free sample will be offered when you need.Mutual effort towards each other.

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Tirzepatide,Polypeptide

    Location:

    Yiwu City, Zhejiang Province

    Payment Terms:

    TT against copy of documents,D/P,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    5 days

    Total Employees:

    5-10

    Year of Establishment:

    2025

  • Inquiry History
    7467 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide

    300 MG Oct 27, 2026
    Canada

    Retatrutide

    1 G Oct 26, 2026
    Switzerland

    Retatrutide

    1 KG Oct 26, 2026
    United States

    Retatrutide

    10 MG Oct 26, 2026
    Australia

    Retatrutide

    30 MG Oct 26, 2026
    United States

    Retatrutide

    30 MG Oct 26, 2026
    United States

    Tesa

    2 MG Oct 25, 2026
    Colombia

    Retatrutide

    15 MG Oct 25, 2026
    United States

    Retatrutide

    10 G Oct 25, 2026
    Canada

    Retatrutide

    1 KG Oct 25, 2026
    United Kingdom

    Retatrutide

    1 G Oct 25, 2026
    Netherlands

    Retatrutide

    10 MG Oct 25, 2026
    Australia

    Retatrutide

    10 MG Oct 25, 2026
    Netherlands

    Retatrutide

    20 MG Oct 25, 2026
    Germany

    Retatrutide

    1 KG Oct 25, 2026
    United Kingdom

    Retatrutide

    10 G Oct 25, 2026
    United States

    Retatrutide

    20 MG Oct 25, 2026
    Poland

    Retatrutide

    20 MG Oct 25, 2026
    United States

    Retatrutide

    10 MT Oct 25, 2026
    United States

    Retatrutide

    300 MG Oct 25, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.